Part D, Rebate-Sharing Rules Slated To Be Proposed This Month
Published by Inside Health Policy
Two rules that are expected to include major policies to curb drug prices are scheduled to be released this month, according to the fall regulatory agenda. However, the agenda’s timetable is often wrong. For example, the agenda estimates that the CMS rule requiring the disclosure of drug prices in TV ads would be proposed in December, even though CMS proposed that rule a day before the agenda was published on Tuesday (Oct. 16).
The White House’s budget office is reviewing two rules, a CMS Part D proposed rule and a proposed rule by the HHS Inspector General on anti-kickback safe harbors, that are expected to include policies aimed at lower drug prices, consultants say.
The Part D proposed rule is considered a possible vehicle for changes to plans’ bidding process, the incorporation of pharmacy price concessions into plan bid cost-sharing amounts and the establishment of point-of-sale rebates. According to the title of the anti-kickback proposal, the HHS Inspector General will propose to both remove current safe harbor protections for drug rebates and create new ones. Sources suspect HHS plans to ban, or limit, rebates that are calculated as a percentage of list prices while allowing rebates used in value-based purchasing arrangements.
Click here to see the original article on the Inside Health Policy website.
Recent Posts
-
SCPC Applauds Bipartisan Group of Lawmakers Calling for Critical Changes to Medicare Drug Price Negotiations
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement commending Chairman Buddy Carter, Rep. Jake Auchincloss and other Members of Congress for urging HHS and CMS to examine the looming impact of Medicare drug price negotiations on America’s pharmacies.
-
SCPC Releases Statement in Support of Government Accountability Office (GAO) Report on the Inflation Reduction Act
SCPC has repeatedly warned about the impact of the Inflation Reduction Act’s (IRA) mandatory Medicare drug price negotiations on LTC pharmacies and the millions of vulnerable seniors they serve. We are glad the Government Accountability Office (GAO) is examining how these policies are affecting pharmacies, particularly LTC pharmacies, which already operate under a broken reimbursement model that often requires them to dispense many of the most commonly used medications at a loss.
-
SCPC Applauds President Trump’s Executive Order Calling on HHS and Congress to Improve the IRA, Rein In PBMs and Lower Drug Costs
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement applauding President Trump’s recent Executive Order aimed at improving the Inflation Reduction Act (IRA), lowering drug prices and addressing the harmful actions of PBMs. “For far too long, pharmacy benefit managers (PBMs) have taken […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.